Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Latest in bladder cancer from the second half of 2025

IPSO guidelines on minimally invasive surgery in paediatric solid tumours

Principles and practice of prognostication

Avoiding burnout

Choosing Wisely: Managing resectable colorectal liver metastases

Common Sense Oncology: Socialist vs Capitalist Oncology

Optimal management of gastric cancers